Development and impact of human papillomavirus vaccines.

Document Type

Article

Publication Date

3-1-2013

Institution/Department

Obstetrics & Gynecology; Oncology

Journal Title

Clinical obstetrics and gynecology

MeSH Headings

Culture, Female, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Humans, Male, Papillomaviridae, Papillomavirus Infections, Papillomavirus Vaccines, Socioeconomic Factors, Uterine Cervical Neoplasms

Abstract

Cervical cancer is a global health crisis that disproportionately affects developing nations and underserved populations. Two vaccines targeting HPV-16 and 18, which account for 70% of invasive cervical carcinomas, are licensed in the United States and numerous countries worldwide. Both vaccine formulations have shown excellent efficacy with minimal toxicity. Numerous questions remain, including cost-effectiveness, vaccination of males, societal acceptance of HPV vaccination, and cervical dysplasia screening in the HPV-immunized population. Access to vaccination for underserved populations both in developed and resource-poor nations remains an issue. Multivalent vaccines that encompass additional oncogenic HPV strains are under development.

ISSN

1532-5520

First Page

10

Last Page

16

Link to Full Text

Share

COinS